Consumption of nattokinase is associated with reduced blood pressure and von Willebrand factor, a cardiovascular risk marker: results from a randomized, double-blind, placebo-controlled, multicenter North American clinical trial
Gitte S Jensen,1 Miki Lenninger,1 Michael P Ero,2 Kathleen F Benson,1 1NIS Labs, Klamath Falls, OR, 2Machaon Diagnostics, Inc., Oakland, CA, USA Objective: The objective of this study is to evaluate the effects of consumption of nattokinase on hypertension in a North American hypertensive population...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-10-01
|
Series: | Integrated Blood Pressure Control |
Subjects: | |
Online Access: | https://www.dovepress.com/consumption-of-nattokinase-is-associated-with-reduced-blood-pressure-a-peer-reviewed-article-IBPC |
id |
doaj-6429d45c34c1484aa7668aa6f5f0555a |
---|---|
record_format |
Article |
spelling |
doaj-6429d45c34c1484aa7668aa6f5f0555a2020-11-25T01:51:10ZengDove Medical PressIntegrated Blood Pressure Control1178-71042016-10-01Volume 99510429408Consumption of nattokinase is associated with reduced blood pressure and von Willebrand factor, a cardiovascular risk marker: results from a randomized, double-blind, placebo-controlled, multicenter North American clinical trialJensen GSLenninger MEro MPBenson KFGitte S Jensen,1 Miki Lenninger,1 Michael P Ero,2 Kathleen F Benson,1 1NIS Labs, Klamath Falls, OR, 2Machaon Diagnostics, Inc., Oakland, CA, USA Objective: The objective of this study is to evaluate the effects of consumption of nattokinase on hypertension in a North American hypertensive population with associated genetic, dietary, and lifestyle factors. This is in extension of, and contrast to, previous studies on Asian populations.Materials and methods: A randomized, double-blind, placebo-controlled, parallel-arm clinical study was performed to evaluate nattokinase (NSK-SD), a fermented soy extract nattō from which vitamin K2 has been removed. Based on the results from previous studies on Asian populations, 79 subjects were enrolled upon screening for elevated blood pressure (BP; systolic BP ≥130 or diastolic BP ≥90 mmHg) who consumed placebo or 100 mg nattokinase/d for the 8-week study duration. Blood collections were performed at baseline and 8 weeks for testing plasma renin activity, von Willebrand factor (vWF), and platelet factor-4. Seventy-four people completed the study with good compliance.Results: Consumption of nattokinase was associated with a reduction in both systolic and diastolic BP. The reduction in systolic BP was seen for both sexes but was more robust in males consuming nattokinase. The average reduction in diastolic BP in the nattokinase group from 87 mmHg to 84 mmHg was statistically significant when compared to that in the group consuming placebo, where the average diastolic BP remained constant at 87 mmHg (P<0.05), and reached a high level of significance for males consuming nattokinase, where the average diastolic BP dropped from 86 mmHg to 81 mmHg (P<0.006). A decrease in vWF was seen in the female population consuming nattokinase (P<0.1). In the subpopulation with low plasma renin activity levels at baseline (<0.29 ng/mL/h), an increase was seen for 66% of the people after 8-week consumption of nattokinase (P<0.1), in contrast to only 8% in the placebo group.Conclusion: The data suggest that nattokinase consumption in a North American population is associated with beneficial changes to BP in a hypertensive population, indicating sex-specific mechanisms of action of nattokinase’s effect on vWF and hypertension. Keywords: subtilisin NAT, systolic blood pressure, diastolic blood pressure, von Willebrand factor, plasma renin activityhttps://www.dovepress.com/consumption-of-nattokinase-is-associated-with-reduced-blood-pressure-a-peer-reviewed-article-IBPCSubtilisin NATsystolic blood pressurediastolic blood pressurevon Willebrand factorplasma Renin activity. |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jensen GS Lenninger M Ero MP Benson KF |
spellingShingle |
Jensen GS Lenninger M Ero MP Benson KF Consumption of nattokinase is associated with reduced blood pressure and von Willebrand factor, a cardiovascular risk marker: results from a randomized, double-blind, placebo-controlled, multicenter North American clinical trial Integrated Blood Pressure Control Subtilisin NAT systolic blood pressure diastolic blood pressure von Willebrand factor plasma Renin activity. |
author_facet |
Jensen GS Lenninger M Ero MP Benson KF |
author_sort |
Jensen GS |
title |
Consumption of nattokinase is associated with reduced blood pressure and von Willebrand factor, a cardiovascular risk marker: results from a randomized, double-blind, placebo-controlled, multicenter North American clinical trial |
title_short |
Consumption of nattokinase is associated with reduced blood pressure and von Willebrand factor, a cardiovascular risk marker: results from a randomized, double-blind, placebo-controlled, multicenter North American clinical trial |
title_full |
Consumption of nattokinase is associated with reduced blood pressure and von Willebrand factor, a cardiovascular risk marker: results from a randomized, double-blind, placebo-controlled, multicenter North American clinical trial |
title_fullStr |
Consumption of nattokinase is associated with reduced blood pressure and von Willebrand factor, a cardiovascular risk marker: results from a randomized, double-blind, placebo-controlled, multicenter North American clinical trial |
title_full_unstemmed |
Consumption of nattokinase is associated with reduced blood pressure and von Willebrand factor, a cardiovascular risk marker: results from a randomized, double-blind, placebo-controlled, multicenter North American clinical trial |
title_sort |
consumption of nattokinase is associated with reduced blood pressure and von willebrand factor, a cardiovascular risk marker: results from a randomized, double-blind, placebo-controlled, multicenter north american clinical trial |
publisher |
Dove Medical Press |
series |
Integrated Blood Pressure Control |
issn |
1178-7104 |
publishDate |
2016-10-01 |
description |
Gitte S Jensen,1 Miki Lenninger,1 Michael P Ero,2 Kathleen F Benson,1 1NIS Labs, Klamath Falls, OR, 2Machaon Diagnostics, Inc., Oakland, CA, USA Objective: The objective of this study is to evaluate the effects of consumption of nattokinase on hypertension in a North American hypertensive population with associated genetic, dietary, and lifestyle factors. This is in extension of, and contrast to, previous studies on Asian populations.Materials and methods: A randomized, double-blind, placebo-controlled, parallel-arm clinical study was performed to evaluate nattokinase (NSK-SD), a fermented soy extract nattō from which vitamin K2 has been removed. Based on the results from previous studies on Asian populations, 79 subjects were enrolled upon screening for elevated blood pressure (BP; systolic BP ≥130 or diastolic BP ≥90 mmHg) who consumed placebo or 100 mg nattokinase/d for the 8-week study duration. Blood collections were performed at baseline and 8 weeks for testing plasma renin activity, von Willebrand factor (vWF), and platelet factor-4. Seventy-four people completed the study with good compliance.Results: Consumption of nattokinase was associated with a reduction in both systolic and diastolic BP. The reduction in systolic BP was seen for both sexes but was more robust in males consuming nattokinase. The average reduction in diastolic BP in the nattokinase group from 87 mmHg to 84 mmHg was statistically significant when compared to that in the group consuming placebo, where the average diastolic BP remained constant at 87 mmHg (P<0.05), and reached a high level of significance for males consuming nattokinase, where the average diastolic BP dropped from 86 mmHg to 81 mmHg (P<0.006). A decrease in vWF was seen in the female population consuming nattokinase (P<0.1). In the subpopulation with low plasma renin activity levels at baseline (<0.29 ng/mL/h), an increase was seen for 66% of the people after 8-week consumption of nattokinase (P<0.1), in contrast to only 8% in the placebo group.Conclusion: The data suggest that nattokinase consumption in a North American population is associated with beneficial changes to BP in a hypertensive population, indicating sex-specific mechanisms of action of nattokinase’s effect on vWF and hypertension. Keywords: subtilisin NAT, systolic blood pressure, diastolic blood pressure, von Willebrand factor, plasma renin activity |
topic |
Subtilisin NAT systolic blood pressure diastolic blood pressure von Willebrand factor plasma Renin activity. |
url |
https://www.dovepress.com/consumption-of-nattokinase-is-associated-with-reduced-blood-pressure-a-peer-reviewed-article-IBPC |
work_keys_str_mv |
AT jensengs consumptionofnattokinaseisassociatedwithreducedbloodpressureandvonwillebrandfactoracardiovascularriskmarkerresultsfromarandomizeddoubleblindplacebocontrolledmulticenternorthamericanclinicaltrial AT lenningerm consumptionofnattokinaseisassociatedwithreducedbloodpressureandvonwillebrandfactoracardiovascularriskmarkerresultsfromarandomizeddoubleblindplacebocontrolledmulticenternorthamericanclinicaltrial AT eromp consumptionofnattokinaseisassociatedwithreducedbloodpressureandvonwillebrandfactoracardiovascularriskmarkerresultsfromarandomizeddoubleblindplacebocontrolledmulticenternorthamericanclinicaltrial AT bensonkf consumptionofnattokinaseisassociatedwithreducedbloodpressureandvonwillebrandfactoracardiovascularriskmarkerresultsfromarandomizeddoubleblindplacebocontrolledmulticenternorthamericanclinicaltrial |
_version_ |
1724998043361607680 |